Research and Markets: Diabetes, Metabolic Syndrome & Cardiovascular Disease: Reshaping Tomorrow's Diabetes Market
Posted on: Thursday, 10 March 2005, 12:00 CST
DUBLIN, Ireland, March 10 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c13803) has announced the addition of Diabetes, Metabolic Syndrome & Cardiovascular Disease: Reshaping Tomorrow's Diabetes Market to their offering.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )
This report takes a comprehensive look at various platform technologies for diabetes, obesity and metabolic diseases. Readers can obtain a complete understanding of the chief diabetes, obesity and metabolic diseases tests -- predictive, screening, prognostic, monitoring, pharmacogenomic, and theranostic -- from their basic principles to their applications and also discover feasible market opportunities via an identification of high-growth applications in different therapeutic areas, with a focus on the biggest and expanding markets for diabetes, obesity and metabolic diseases.
This report provides an in-depth analysis of the major world markets for molecular diagnostics, including forecasts for growth and also includes market figures regarding the current value of the diabetes drug market. Projections and forecasts for the future of the diabetes market ranges from 2004 to 2010.
This report covers the following categories of diabetes drugs:
- Rapid Acting Insulin
- Short Activity Insulin
- Intermediate Acting Insulin
- Long Acting Insulin
- Ultra Long Acting Insulin
- Insulin Mixtures
- Sulfonylureas
- Meglitinides
- Biguanides
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
Analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research into the illness provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible research and development budgets. Company-specific information, including sales figures, drug pipeline status, and research and development trends is provided throughout the report.
This report answers the following questions:
- What are the near term business opportunities in the diabetes, obesity
and metabolic disease market?
- What are the current and forecasted sizes of the diabetes, obesity and
metabolic disease market market?
- What are the business models currently used by companies in diabetes,
obesity and metabolic disease market?
- How will drug manufacturers, researchers, physicians, patients and
payers influence the diabetes, obesity and metabolic disease market?
- What are the drivers and bottlenecks influencing the diabetes, obesity
and metabolic disease market?
- What are the technologies used in diabetes, obesity and metabolic
disease therapies?
- Who holds the proprietary rights to diabetes, obesity and metabolic
disease market therapeutic technology?
- What are current applications of this technology?
- What regulatory processes must diabetes, obesity and metabolic disease
therapeutics undergo in the U.S., Japan and Europe?
- How will new diabetes, obesity and metabolic disease therapies change
treatment and payment paradigms?
- How will litigation concerns increase physician use of diabetes, obesity
and metabolic disease therapies?
- How will diabetes, obesity and metabolic disease therapies reduce
adverse drug reactions and decrease total patient care cost?
- How will diabetes, obesity and metabolic disease therapies reduce health
care expenditures?
- How will drug development cost and time decrease with diabetes, obesity
and metabolic disease therapy use?
Contents Include:
- Overview
- Introduction
- Understanding the Metabolic Conditions Underlying and Associated With
Diabetes
- Current Treatment Paradigms
- Emerging Oral Antidiabetes Products
- Projections for the Antidiabetes Drug Market
- Diagnosing Diabetes with in vitro Laboratory Tests
- Insulin Delivery Technologies
- Market Trends, Challenges, and Strategic Options
- Company Profiles
- Abbott Laboratories
- Aerogen
- Alkermes
- Alteon
- Amlyn Pharmaceuticals, Inc
- Aradigm
- AstraZeneca plc
- Aventis
- Bayer
- Cephalon, Inc.
- Conjuchem
- Eli Lilly and Company
- Emisphere Technologies
- Generex Biotechnology Corporation
- GlaxoSmithKline plc
- Keryx Biopharmaceuticals, Inc.
- Merck
- Merial
- Nastech Pharmaceuticals
- Nektar Therapeutics, Inc
- Novo Nordisk A/S
- Pfizer, Inc.
- Roche
- Takeda
- TAP Pharmaceutical Products Inc.
- Biosante Pharmaceuticals, Inc.
- Insmed, Inc.
- Neurocrine Biosciences
- Phenomix Corp.
- Theratechnologies
- Bioval
For more information visit http://www.researchandmarkets.com/reports/c13803
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980
Photo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH
Research and Markets
CONTACT: Laura Wood, Senior Manager, Research and Markets,press@researchandmarkets.com, Fax: +353-1-4100-980
Web site: http://www.researchandmarkets.com/reports/c13803
Source: PRNewswire
Related Articles
- Drugs, Surgery Produce Similar Death Rates in Diabetics With Heart Disease
- Parkinson's Disease Market Upgrade Following Evidence of Disease Slowing With Azilect
- INC Research Appoints Head of Metabolic & Endocrine Diseases Clinical Division
- Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From 2006 Levels
- There Are Currently 165 Therapeutics Targeting Pancreatic Cancer, From Early Preclinical To Marketed Drugs
- Drug Compliance Programs Demand Market Research Support
- Dr. Luciano Rossetti, Internationally-Recognized Physician and Researcher, Joins Merck Research Laboratories in Key Leadership Role; Will Focus on Developing New Treatments for Diabetes and Obesity, Two Growing Global Health Problems
- Change in CEO at N.J. Drug Market Research Firm
- Research and Markets: Business Opportunities in Diabetes, Obesity and Metabolic Disease Market Analysed
 |
 |
User Comments (0)
RSS Feeds